Document is current
Any future updates will be listed below
-
Authors
Fishman, Jesse
Kim, Yestle
Charlton, Michael R.
Smith, Zachary J.
O’Connell, Tom
Bercaw, Eric M. https://orcid.org/0009-0000-6471-9936
-
Funding
Funding for this research was provided by:
Madrigal Pharmaceuticals
- License Information
-
More Information
Article History
Received: 14 June 2024
Accepted: 2 September 2024
First Online: 18 September 2024
Declarations
:
: Jesse Fishman was previously an employee of Madrigal Pharmaceuticals, Inc. and previously owned stock options from Madrigal Pharmaceuticals, Inc. Yestle Kim is an employee of Madrigal Pharmaceuticals, Inc., and may own stocks/and or options from Madrigal Pharmaceuticals Inc. Michael R. Charlton has received advisory and consulting honoraria from Madrigal, Novo Nordisk, Cytodyn, Terns, Alnylam, AMR, Glympse, Northsea, Sagmimet, Genentech, and Merck; he has also received research grants from Pfizer and Madrigal, unrelated to this work. Eric M. Bercaw and Tom O’Connell are employees of Medicus Economics, LLC. Medicus Economics, LLC received consulting fees for research from Madrigal Pharmaceuticals, Inc. Zachary J. Smith was previously an employee of Medicus Economics, LLC at the time of development of this manuscript. Medicus Economics, LLC received consulting fees for research from Madrigal Pharmaceuticals, Inc.
: This manuscript is based on previously conducted studies and does not contain any new studies with human participants performed by any of the authors.
